TSC2

Across TCGA pan-cancer cohorts, TSC2 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of TSC2’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where TSC2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TSC2 is over-expressed in tumor, although a few such as THCA and BLCA show the opposite, repressed pattern.

LIHC, COAD, and THCA are the cancer types where TSC2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TSC2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+1.356	<.001	9	view →
COAD	All	All	+0.477	<.001	8	view →
THCA	All	II,III,IV	−0.466	<.001	8	view →
KIRP	All	II,III,IV	+0.407	.005	6	view →
CHOL	Male	All	+1.960	<.001	3	view →
KIRC	Female	All	+0.376	.004	3	view →
BLCA	All	IV	−0.780	.002	2	view →
PAAD	Male	All	+0.390	.036	2	view →
HNSC	All	All	+0.256	.015	2	view →
LUAD	All	III,IV	+0.411	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

TSC2–LIHC

Open the LIHC breakdown →